73876-07-0Relevant academic research and scientific papers
FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS
-
Paragraph 0253, (2020/05/15)
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to nicotinamide phosphoribosyltransferase (NAM FT) expression. More particularly, this disclosure relates to fused bicyclic heterocyclic compounds and pharmaceutical compositions thereof, methods of inhibiting NAM FT with these compounds, and methods of treating diseases related to NAMPT expression.
